Typhoid fever remains to be a serious disease burden worldwide with an estimated annual
incidence about 20 million. The licensed vaccines showed moderate protections and have …

On September 22 to 25, 2002, a group of infectious disease specialists, public health
officials, and vaccine experts from 33 countries gathered in Scottsdale, Arizona, to discuss …

Concentrations of serum anti—Haemophilus influenzae type b (anti-Hib) capsular
polysaccharide (CPS)⩾ 0.15 and⩾ 1.0 µ g/mL are widely used as surrogates for protection …

We performed a double-blind clinical study to evaluate the safety and immunogenicity of four
formulations of a DTwPHib full liquid vaccine, three of which contained fractional doses of …

In a double-blind, randomized, and placebo-controlled previous trial, the efficacy of Vi-r EPA
for typhoid fever in 2-to 5-year-olds was 89.0% for 46 months. Vi-r EPA contained 25 μg of Vi …

Determination of antibody avidity measurements can be difficult in human serum depending
on the population evaluated. We evaluated three approaches for the determination of …

Haemophilus influenzae (Hi) is responsible for significant morbidity and mortality worldwide,
particularly in children under 5 years of age. In the pre-vaccine era, 95% of serious disease …

We evaluated the functional activities of antibodies, serum bactericidal activity (SBA), and
immunoglobulin G (IgG) antibody avidity indices, using sodium thiocyanate (NaSCN) …

Immunogenicity data obtained after primary series immunisations against Haemophilus
influenzae type b (Hib), using a vaccine prepared by conjugating the capsular …

Haemophilus influenzae type b (Hib) is responsible for significant morbidity and mortality
worldwide, particularly in children under 5 years of age. In countries where the Hib …